綠谷製藥九期一海外臨牀試驗停止？迴應稱正與監管溝通
5月11日，綠谷製藥的阿爾茨海默症藥物GV-971的國際III期臨牀試驗已經停止。已有5家臨牀試驗中心證實了該消息。對此，綠谷製藥迴應稱，公司正在和監管進行溝通，預計本週會發布相關公告。GV-971是全球首款靶向腦腸軸的阿爾茨海默病（AD）藥物。其於2019年11月在國內獲國家藥監局有條件批准上市。2021年12月，GV-971經過談判被納入國家醫保目錄，每月醫療費用從3580元人民幣降至1184元人民幣。 (北京商報)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
👍